CARLSBAD, Calif. and NEW HAVEN, Conn., Feb. 19 /PRNewswire-FirstCall/ -- Genoptix, Inc. , a specialized laboratory service provider, and HistoRx, Inc. (privately held), a diagnostics company, today announced a multi-year licensing agreement for AQUA(R) technology and several diagnostic assays based on it. Genoptix has obtained exclusive commercial laboratory rights in the United States to develop and perform three solid tumor assays using HistoRx’s proprietary technology for analysis of fluorescent immunohistochemistry (fIHC), enabling quantitative assessment of specific biomarkers for patients with certain solid tumors.
“We are delighted to be working with HistoRx and look forward to developing and validating clinical diagnostics for key biomarkers using AQUA technology, and to offering them to our oncologist customers and their patients,” said Mike Nerenberg, M.D., Senior Vice President and Chief Technical Officer of Genoptix. “Standard immunohistochemistry assays have their value when detection of biomarkers is sufficient, but clinicians are increasingly discovering that true quantitation of protein in tumors enables more powerful insights. AQUA technology is noted for its reproducible quantitation of protein biomarkers in tissue and the agreement we announce today will enhance Genoptix’s ability to address growing market needs.”
AQUA technology quantifies and compartmentalizes (e.g., through the measurement of protein in the cell’s cytoplasm or nucleus) tumor markers, an important component of the assessment of solid tumors for individual cancer patients.
About HistoRx, Inc.
HistoRx, Inc. is a leading developer of tissue-based diagnostic solutions to advance individualized patient care. The company’s products and services are based on proprietary analysis of tissue biomarkers using AQUA(R) technology. AQUA(R) technology is the only platform capable of precisely measuring protein biomarker concentration with sub-cellular resolution in tissue sections, enabling fully objective, standardized, reproducible, and automated analysis to guide drug development and therapeutic decision-making. HistoRx is commercializing a pipeline of proprietary diagnostic products targeting improved treatment decision-making and patient outcomes in cancer care. For more information, please visit www.historx.com.
CONTACT: Kathleen Q. Adams, VP, Diagnostics Marketing of HistoRx,
+1-203-498-7500, Kathleen.Adams@historx.com; or Marcy Graham, Executive
Director, Investor Relations of Genoptix, Inc., +1-760-930-7150,
investorrelations@genoptix.com; or Sarah Thailing, Principal of Wordanista,
+1-619-994-1895, sarah@wordanista.com, for Genoptix, Inc.
Web site: http://www.genoptix.com/
http://www.historx.com/
